Treace

Treace Medical Concepts, Inc. develops and commercialises 3D surgical correction systems and related instruments for bunion and midfoot deformities in foot and ankle orthopedics. Founded in 2014 and headquartered in Ponte Vedra, Florida, the company is publicly listed on NASDAQ under the ticker TMCI. Its flagship offering, Lapiplasty® 3D Bunion Correction®, addresses all three dimensions of bunion deformity rather than the conventional two-dimensional approach.

The portfolio extends beyond bunion correction. Adductoplasty® targets midfoot deformity, SpeedMTP® addresses metatarsophalangeal joint procedures, and Nanoplasty® and Percuplasty™ provide minimally invasive and percutaneous deformity correction options. IntelliGuide™ PSI supplies patient-specific instrumentation designed to make surgical outcomes reproducible and guided.

Manufacturing draws on additive manufacturing techniques including DMLS metal 3D printing and Nylon 12 3D printing, carried out at Class 8 cleanroom facilities. The company's technical work spans minimally invasive surgical techniques, clinical research and medical education.

Treace runs a medical education programme built around hands-on cadaveric training led by experienced surgeon faculty, and reports that thousands of surgeons worldwide have been trained on its systems. The company states a strong commitment to clinical research and peer-reviewed evidence, with extensive peer-reviewed studies validating its 3D Correction® systems.